ASH 2022 | 5-year update of BFORE: bosutinib vs imatinib in CML
Jorge Cortes, MD, Augusta University, Augusta, GA, summarizes the design and updated findings of the BFORE trial (NCT02130557), which compared the efficacy and toxicity profiles of bosutinib and imatinib in patients with newly diagnosed chronic myeloid leukemia (CML). This study confirmed that bosutinib can be a high-efficacy frontline treatment for patients with CML with a safety profile similar to that of imatinib. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultant for Pfizer, Novartis, Takeda, Sun Pharma, Rigel and Forma Therapeutics. Dr Cortes’ institution receives research support from Pfizer, Takeda, Novartis and Sun Pharma.
